Dengue vaccines: progress and challenges

被引:84
作者
Coller, Beth-Ann G. [1 ]
Clements, David E. [1 ]
机构
[1] Merck & Co Inc, Vaccines Res, West Point, PA 19486 USA
关键词
HEMORRHAGIC-FEVER; CELLULAR-IMMUNITY; DISEASE SEVERITY; SOUTHEAST-ASIA; CLINICAL-TRIAL; PUBLIC-HEALTH; SEROTYPES; VIRUS; ANTIBODIES; NAIVE;
D O I
10.1016/j.coi.2011.03.005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
With several dengue vaccine candidates progressing through clinical trials, several options for controlling this disease appear feasible. This would represent a major achievement and reflect decades of research and development activities. The challenges associated with the limited understanding of protective responses and those factors which determine disease severity remain, but with prospective studies ongoing in various dengue endemic areas and the initiation of dengue vaccine efficacy trials, immune responses are being evaluated in the context of protection and severe disease and these studies are highly likely to provide additional insights.
引用
收藏
页码:391 / 398
页数:8
相关论文
共 66 条
[31]   Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults [J].
Kitchener, S ;
Nissen, M ;
Nasveld, P ;
Forrat, R ;
Yoksan, S ;
Lang, J ;
Saluzzo, JF .
VACCINE, 2006, 24 (09) :1238-1241
[32]  
Knowlton K., 2009, MOSQUITO BORNE DENGU
[33]   Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II [J].
Lai, Chih-Yun ;
Tsai, Wen-Yang ;
Lin, Su-Ru ;
Kao, Chuan-Liang ;
Hu, Hsien-Ping ;
King, Chwan-Chuen ;
Wu, Han-Chung ;
Chang, Gwong-Jen ;
Wang, Wei-Kung .
JOURNAL OF VIROLOGY, 2008, 82 (13) :6631-6643
[34]   Consequences of the Expanding Global Distribution of Aedes albopictus for Dengue Virus Transmission [J].
Lambrechts, Louis ;
Scott, Thomas W. ;
Gubler, Duane J. .
PLOS NEGLECTED TROPICAL DISEASES, 2010, 4 (05)
[35]   Recent progress on sanofi pasteur's dengue vaccine candidate [J].
Lang, Jean .
JOURNAL OF CLINICAL VIROLOGY, 2009, 46 :S20-S24
[36]   Dengue virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection [J].
Laoprasopwattana, K ;
Libraty, DH ;
Endy, TP ;
Nisalak, A ;
Chunsuttiwat, S ;
Vaughn, DW ;
Reed, G ;
Ennis, FA ;
Rothman, AL ;
Green, S .
JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (03) :510-519
[37]   A Prospective Nested Case-Control Study of Dengue in Infants: Rethinking and Refining the Antibody-Dependent Enhancement Dengue Hemorrhagic Fever Model [J].
Libraty, Daniel H. ;
Acosta, Luz P. ;
Tallo, Veronica ;
Segubre-Mercado, Edelwisa ;
Bautista, Analisa ;
Potts, James A. ;
Jarman, Richard G. ;
Yoon, In-Kyu ;
Gibbons, Robert V. ;
Brion, Job D. ;
Capeding, Rosario Z. .
PLOS MEDICINE, 2009, 6 (10)
[38]   Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections [J].
Libraty, DH ;
Endy, TP ;
Houng, HSH ;
Green, S ;
Kalayanarooj, S ;
Suntayakorn, S ;
Chansiriwongs, W ;
Vaughn, DW ;
Nisalak, A ;
Ennis, FA ;
Rothman, AL .
JOURNAL OF INFECTIOUS DISEASES, 2002, 185 (09) :1213-1221
[39]   The Epidemiology of Dengue in the Americas Over the Last Three Decades: A Worrisome Reality [J].
Luis San Martin, Jose ;
Brathwaite, Olivia ;
Zambrano, Betzana ;
Orlando Solorzano, Jose ;
Bouckenooghe, Alain ;
Dayan, Gustavo H. ;
Guzman, Maria G. .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2010, 82 (01) :128-135
[40]   Understanding the contribution of cellular immunity to dengue disease pathogenesis [J].
Mathew, Anuja ;
Rothman, Alan L. .
IMMUNOLOGICAL REVIEWS, 2008, 225 :300-313